环磷腺苷葡胺治疗婴幼儿喘息性疾病疗效观察

Clinical effect of meglumine adenosine cyclophosphate in the treatment of infantile asthmatic diseases

目的观察环磷腺苷葡胺治疗婴幼儿喘息性疾病的临床疗效与安全性。方法 2014年8月至2016年6月铜陵市妇幼保健院儿科收治住院的婴幼儿喘息性疾病100例,随机分为观察组和对照组各50例。两组均给予常规治疗,观察组给予环磷腺苷葡胺注射液静脉滴注及布地奈德雾化吸入,对照组给予甲泼尼龙注射液静脉滴注及布地奈德雾化吸入,疗程5d。观察两组患儿临床疗效,喘息、咳嗽、肺部体征改善时间,住院时间及不良反应。结果观察组总有效率为98.0%(49/50),对照组总有效率为96.0%(48/50),两组比较差异无统计学意义(P>0.05)。两组患儿咳嗽、喘息、肺部喘鸣音临床症状体征改善时间与住院时间比较,差异无统计学意义(P>0.05)。两组均未见不良反应发生,对照组因全身使用糖皮质激素,发生院内感染4例。结论环磷腺苷葡胺治疗婴幼儿喘息性疾病效果与全身使用糖皮质激素疗效相当,安全性好,值得临床推广使用。

Objective To observe the clinical effect and safety of meglumine adenosine cyclophosphate in the treatment of infants with asthmatic diseases.Methods A total of 100 cases of infantile asthmatic diseases treated in Tongling Maternal and Child Healthcare Hospital from Aug.2014 to June 2016 were randomly divided into two groups:observation group and control group,50 cases in each.Both groups were given conventional treatment;in addition,the observation group was given meglumine adenosine cyclophosphate injection for intravenous dripping and budisonide for inhalation,while the control group received methylprednisolone injection for intravenous dripping and budisonide for inhalation,the treatment lasting for 5 days.Observe the clinical effect,the time for wheezing,cough and pulmonary symptoms to be relieved,the length of hospital stay and adverse reactions in the children of the two groups.Results The total effective rate was 98.0%(49/50)in the observation group,and 96.0%(48/50)in the control group,there being no statistical difference between the two groups(P>0.05).There was no statistical difference in the relief time of such clinical symptoms as cough,wheezing,lung wheezing rales or the length of hospital stay between the two groups(P>0.05).There was no adverse reaction in both groups.There were 4 cases of infection in the control group because of the use of glucocorticoid in the whole body.Conclusion The effect of meglumine adenosine cyclophosphate in the treatment of infants with asthmatic diseases is similar to that of the use of glucocorticoid in the whole body;it's safe and worthy of clinical application.